Jade Biosciences JBIO Institutional Ownership

Updated Oct 11, 2026

Jade Biosciences, Inc. (NASDAQ:JBIO) counted 154 institutional investors among its 13F-reported shareholders for the quarter ended June 30, 2026.

• Total shares held in Jade Biosciences rose 46.28% versus Q1 2026, while the number of holders rose 113.89% versus Q2 2025.
• Among the 154 holders of Jade Biosciences, 113 added to their positions, 25 reduced their stakes and 16 left their positions unchanged.
• Combined, institutional investors held 72.92Mn shares of JBIO as of Q2 2026, up 23.07Mn from the prior quarter and up 41.44Mn from a year earlier.
• As of June 30, 2026, the biggest holder of Jade Biosciences was FMR LLC with 9.13Mn shares.
• Among holders that already owned Jade Biosciences, the biggest buyers in Q2 2026 were FMR LLC (+2.04Mn shares), State Street Corp (+1.68Mn shares), JPMorgan Chase & Co (+1.46Mn shares), Citadel Advisors LLC (+792.18K shares) and Soleus Capital Management, L.P. (+753.95K shares).
• Holders that trimmed the most shares of Jade Biosciences in Q2 2026 while keeping a position were Versant Venture Management, LLC (-534.04K shares), Bellevue Group AG (-443.51K shares), Baker Bros. Advisors LP (-410.71K shares), Marshall Wace, LLP (-359.01K shares) and Opaleye Management Inc. (-282.61K shares).
• According to Business Quant data, the leading holders of JBIO for Q2 2026 were FMR LLC (9.13Mn shares), Jupiter Topco LLC (6.27Mn shares), Fairmount Funds Management LLC (4.55Mn shares), Ra Capital Management, L.P. (3.67Mn shares), Venrock Adviser, LLC (3.22Mn shares), Bellevue Group AG (3.06Mn shares), Paradigm Biocapital Advisors LP (2.86Mn shares), BlackRock, Inc. (2.8Mn shares), Franklin Templeton Inc (2.79Mn shares) and State Street Corp (2.34Mn shares).